DOSAGE INDEX / BLEND
CJC-1295 NO DAC + Ipamorelin
Research, reported schedules and supply planning.
Evaluate the No DAC identity question, ipamorelin component evidence and the direct comparisons needed to validate this exact peptide blend.
Source: PeptideDosages.com. Independently written summaries of reported protocols, not validated treatment recommendations. Reviewed for transcription on September 21, 2026.
Research Protocol & Dosage
Source-reported examples · not treatment recommendations
- Amount
- 100–300 micrograms of each component per day
- Frequency
- Once daily
- Cycle / observation period
- 8–12 weeks; source also mentions 16 weeks
- Route / research model
- Subcutaneous
The source assumes equal component amounts. Clinical validation of this exact combined regimen is not established by this summary.
Titration & progression
A dose range is not a titration schedule. No independently verified stepwise escalation has been established for this source-reported regimen.
Supply & Planning
Compare vial strengths here. A different vial size changes the available material, not the biological dose.
Diluent & formulation
Diluent compatibility is formulation-specific. A verified manufacturer instruction is still needed before bacteriostatic water or another diluent can be listed as suitable for this research material.
Vial comparison
No single complete schedule is resolved for this entry. Enter a documented total to compare strengths; the calculator does not select a regimen.
| Vial strength | Vials needed |
|---|---|
| 10 mg | Enter a total |
Enter a positive material total.
Material minimum only: round total material ÷ vial content up to a whole vial. Actual supply may be higher because of single-use packaging, discard dates, dead space or losses. No validated multi-use storage period is assumed.
Reported Research Results
Selected observations from the cited research. Each finding retains its study population, formulation and limitations.
Studies of individual ingredients do not establish the effects of this finished combination. Combination studies are identified explicitly below.
- FDA's 2024 scientific briefing treats CJC-1295 and its DAC form as different active moieties. The long-acting form's human findings should therefore remain attached to that material. [1]
- A human volunteer study characterized ipamorelin exposure and GH release after intravenous administration. It did not test this No DAC blend. [2]
- An older human experiment examined GHRH(1-29) with GHRP-2 and did not demonstrate synergy under its tested conditions. Those were different materials from this listing. [3]
Sourcing & Vendor Information
No compound-specific affiliate destination is listed here yet. Browse the Vendors Index for the available supplier records and disclosed relationships.
Sources & Further Reading
Medical publications and supporting literature from the corresponding protocol bibliographies, combined across vial strengths. Supplier and commercial catalog references are excluded. Duplicate destinations appear once. Inclusion does not mean that a paper validates the reported dose, or that an ingredient study tests the finished blend.
Bibliography checked September 22, 2026: 13 entries mapped from 1 source page. Medical and supporting references are retained below; supplier entries are excluded.
- FDA scientific assessment
- Original ipamorelin study
- Original related experiment
- PubMedFurther reading · Listed in reference bibliography.
- PubMedFurther reading · Listed in reference bibliography.
- PubMedFurther reading · Listed in reference bibliography.
- PMCFurther reading · Listed in reference bibliography.
- PubMedFurther reading · Listed in reference bibliography.
- CDCGeneral guidance · Listed in reference bibliography.
- CDC (Subcut Injection PDF)General guidance · Listed in reference bibliography.
- NCBI BookshelfFurther reading · Listed in reference bibliography.
- Subcutaneous Drug Injection Review (PMC)Further reading · Listed in reference bibliography.
- Frontiers in EndocrinologyFurther reading · Listed in reference bibliography.
- Endocrine ReviewsFurther reading · Listed in reference bibliography.
Reported schedule reference: PeptideDosages.com. Research findings are summarized independently from the listed sources.